Combinations Key For Amgen’s Lumakras, But PD-1/L1 Data Held Until August
Combo Importance Increases With Sales Growth Slowing
A World Conference on Lung Cancer abstract shows responses to Lumakras with a SHP2 inhibitor but closely watched results for anti-PD-1/L1 combinations are under embargo until the meeting next month.
